1. Placental Passage of Protopine in an Ex Vivo Human Perfusion System
- Author
-
Spiess, Deborah; https://orcid.org/0000-0001-8887-6194, Abegg, Vanessa Fabienne, Chauveau, Antoine, Treyer, Andrea, Reinehr, Michael; https://orcid.org/0000-0003-3321-0920, Oufir, Mouhssin, Duong, Elisa, Potterat, Olivier; https://orcid.org/0000-0001-5962-6516, Hamburger, Matthias; https://orcid.org/0000-0001-9331-273X, Simões-Wüst, Ana Paula; https://orcid.org/0000-0002-4489-0952, Spiess, Deborah; https://orcid.org/0000-0001-8887-6194, Abegg, Vanessa Fabienne, Chauveau, Antoine, Treyer, Andrea, Reinehr, Michael; https://orcid.org/0000-0003-3321-0920, Oufir, Mouhssin, Duong, Elisa, Potterat, Olivier; https://orcid.org/0000-0001-5962-6516, Hamburger, Matthias; https://orcid.org/0000-0001-9331-273X, and Simões-Wüst, Ana Paula; https://orcid.org/0000-0002-4489-0952
- Abstract
The placental passage of protopine was investigated with a human ex vivo placental perfusion model. The model was first validated with diazepam and citalopram, 2 compounds known to cross the placental barrier, and antipyrine as a positive control. All compounds were quantified by partially validated U(H)PLC-MS/MS bioanalytical methods. Protopine was transferred from the maternal to the fetal circuit, with a steady-state reached after 90 min. The study compound did not affect placental viability or functionality, as glucose consumption, lactate production, and beta-human chorionic gonadotropin, and leptin release remained constant. Histopathological evaluation of all placental specimens showed unremarkable, age-appropriate parenchymal maturation with no pathologic findings.
- Published
- 2022